Be currently implanted with Rheos system and have completed the 13-month follow-up period.
Be on stable anti-hypertensive therapy for at least 4 weeks prior to inclusion, where stable is defined as no changes in medications or dosage of medications.
Have at least one functional carotid baroreflex activation electrode.
Have signed and approved informed consent form for participation in this study.
You may not be if
Myocardial infarction (MI) or cerebral vascular accident (CVA) within the past 90 days, or subject is still unstable from a prior MI or CVA that occurred more than 90 days ago.
Are unable or unwilling to comply with the protocol requirements of this study.
Diagnosed with severe chronic obstructive lung disease (COPD/asthma GOLD stadium III and IV).
